- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06601101
Effekter av aktuellt insulin på läkning av korneala epitel efter korneal tvärbindning hos patienter med keratokonus
Effekter av aktuellt insulin på läkning av hornhinneepitel efter korneal tvärbindning hos patienter med keratokonus: en randomiserad klinisk prövning
The cornea plays a fundamental role in vision, being a complex tissue essential for ocular health. In ophthalmological practice, there are situations such as corneal crosslinking, where damage to the corneal epithelium occurs. Crosslinking is a surgical procedure aimed at strengthening collagen bonds in the corneal stroma to prevent the progression of keratoconus, through the application of topical riboflavin followed by ultraviolet (UV-A) radiation. To enhance the effectiveness of riboflavin and UV-A radiation, the corneal epithelium needs to be removed, which can cause postoperative pain and discomfort, as well as increase the risk of complications such as infections, scarring, corneal opacities, perforations, and recurrent epithelial erosions. Several growth factors play a role in epithelial healing, and the discovery of insulin in the tear film and the presence of insulin and Insulin-Like Growth Factor (IGF-1) receptors in the cornea has raised the hypothesis that insulin may modulate the cornea's wound healing response. Since then, topical insulin has been used for various ocular pathologies, including dry eye disease, persistent epithelial defects, and neurotrophic ulcers. Based on this knowledge, studies have been developed, and promising results regarding the use of insulin in corneal healing have been reported, providing a scientific foundation for the realization of this project.
The objective of this study was to evaluate the effect of insulin eye drops at a concentration of 50 IU/ml on epithelial healing in non-diabetic patients undergoing epithelial debridement for corneal crosslinking. To this end, a randomized, double-masked clinical trial was conducted with two groups, one being the control group, in which researchers compared the epithelial healing rate in mm²/h between the insulin group and the placebo group, as the primary outcome. Patients diagnosed with keratoconus and with an indication for the crosslinking procedure were invited to participate.
The study was designed to assess and quantify the impact of topical insulin on epithelial defect closure in patients undergoing crosslinking, compared to placebo.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Patients from the Keratoconus Clinic of the Hospital de Clínicas, State University of Campinas (UNICAMP), Brazil, with a diagnosis of keratoconus and an indication for corneal crosslinking were evaluated with visual acuity, refraction, slit-lamp biomicroscopy, Goldmann applanation tonometry, corneal specular microscopy (EM-3000, Tomey) for endothelial cell count, and corneal tomography (Pentacam HR, Oculus).
Eligible patients who signed the informed consent form (with the legal guardian also signing for participants younger than 18 years) underwent crosslinking. After the procedure, participants were allocated to two groups (insulin and placebo) by block randomization with blocks of four, stratified by sex. The random sequence was generated at random.org/lists and concealed in sealed opaque envelopes prepared by an independent assistant. Envelopes were opened sequentially at enrollment by investigators who did not take part in outcome assessment. One participant underwent crosslinking in both eyes, which were allocated to different groups; the eye was the unit of analysis.
Crosslinking was standardized for all participants and performed by third-year ophthalmology residents supervised by attending physicians. Central 8.0-mm epithelial debridement was performed with an optical zone marker of the same diameter: 30% alcohol was applied within the marker for 10 seconds and dried with an ophthalmic sponge, and the epithelium was removed with a corneal scarifier spatula. Riboflavin 0.1% (400 mOsm) in a hydroxypropyl methylcellulose vehicle was used, with UVA irradiation at 9 mW/cm² for 10 minutes (fluence 5.4 J/cm²) using the Eyelink Crosslink device (Eyetec, São Carlos, Brazil). At the end of the procedure, the size and shape of the debrided area were checked with the 8.0-mm marker, and participants whose debridement did not meet this standard were excluded.
The insulin group received NPH insulin 50 IU/mL eye drops (Eye Pharma, São Paulo, Brazil) four times daily, and the placebo group received 0.5% methylcellulose eye drops (Eye Pharma), the vehicle of the insulin formulation, four times daily, until complete epithelial healing. The bottles were identical and were labeled on the prescription as "compounded eye drops". Participants and outcome assessors were masked to group allocation. Both groups received moxifloxacin 5 mg/mL every 6 hours (Oftalmox; Geolab), prednisolone acetate 10 mg/mL every 6 hours (Ster; União Química), 0.15% sodium hyaluronate every 4 hours (Hyabak; Laboratoires Théa) and a silicone hydrogel bandage contact lens (Air Optix plus HydraGlyde; Alcon) until complete epithelial healing. Moxifloxacin and the study eye drops were then discontinued, and prednisolone was tapered weekly until one month after the procedure.
Crosslinking was always performed on Tuesdays, and assessments took place 18, 42 and 66 hours after the procedure (postoperative days 1 to 3). If epithelialization was incomplete at 66 hours, a further visit was scheduled on postoperative day 6 and every 48 hours thereafter until complete epithelialization. At each visit, the epithelial defect was photographed with the Keratograph 5M (OCULUS) and slit-lamp biomicroscopy was performed. The defect area was measured with ImageJ software by an investigator masked to allocation and reviewed independently by a second masked investigator. Complete epithelial healing was defined as the absence of an epithelial defect after fluorescein instillation on Keratograph 5M images, confirmed by two examiners on slit-lamp examination.
The primary outcome is the corneal epithelialization rate (mm²/h). Secondary outcomes are time to complete epithelialization and adverse events, in addition to endothelial cell density. Later follow-up visits took place at 30 and 60 days after crosslinking.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
São Paulo
-
Campinas, São Paulo, Brasilien, 13.083-887
- State University of Campinas
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age 14 years or older
- Diagnosis of keratoconus with an indication for corneal crosslinking
Exclusion Criteria:
- Diabetes mellitus
- Dry eye disease
- Limbal stem cell deficiency
- Glaucoma
- Allergy to insulin or methylcellulose
- Irregular epithelial debridement and/or debridement other than 8.0 mm during the crosslinking procedure
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Insulin
NPH insulin 50 IU/mL eye drops (Eye Pharma, São Paulo, SP, Brazil), one drop four times daily until complete corneal epithelialization, added to the standard postoperative regimen. |
Insulin eye drops in the postoperative prescription for corneal crosslinking
Andra namn:
|
|
Placebo-jämförare: Placebo
0.5% methylcellulose eye drops (Eye Pharma, São Paulo, SP, Brazil), the vehicle of the insulin formulation, one drop four times daily until complete corneal epithelialization, added to the standard postoperative regimen. |
Placebo eye drops of 0.5% Methylcellulose in the postoperative prescription for corneal crosslinking
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Corneal Epithelial Healing Rate
Tidsram: From crosslinking until complete epithelialization, assessed at 18, 42 and 66 hours, on day 6 and every 48 hours thereafter.
|
Rate of corneal re-epithelialization (mm²/h), calculated as the epithelial defect area at the first postoperative assessment (18 hours) divided by the time elapsed until complete epithelialization. Defect area measured on Keratograph 5M (OCULUS) images with ImageJ software by masked investigators. |
From crosslinking until complete epithelialization, assessed at 18, 42 and 66 hours, on day 6 and every 48 hours thereafter.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Endothelial cell count
Tidsram: 60 days
|
Endothelial cell count loss in each group, if any |
60 days
|
|
Incidence of corneal haze
Tidsram: 60 days.
|
Incidence of corneal haze in each group. |
60 days.
|
|
Time to complete epithelialization
Tidsram: From crosslinking until complete epithelialization.
|
Time (hours) from crosslinking to the first assessment at which complete epithelial closure was documented (absence of an epithelial defect after fluorescein instillation on Keratograph 5M images, confirmed on slit-lamp examination). Closure could only be ascertained at scheduled visits. |
From crosslinking until complete epithelialization.
|
|
Adverse events
Tidsram: From crosslinking until the end of follow-up.
|
Number of eyes with ocular adverse events (e.g., infectious keratitis, sterile infiltrates, persistent epithelial defect, allergic reaction to study eye drops) recorded at each study visit. |
From crosslinking until the end of follow-up.
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Epithelial Defect Area
Tidsram: 18, 42 and 66 hours after crosslinking.
|
Area of the corneal epithelial defect (mm²) measured on Keratograph 5M images with ImageJ software. |
18, 42 and 66 hours after crosslinking.
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Studiestol: Monica Alves, PhD, State University of Campinas (Unicamp)
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Ögonsjukdomar
- Keratokonus
- Kornea sjukdomar
- Hormoner
- Hormoner, hormonsubstitut och hormonantagonister
- Farmaceutiska lösningar
- Peptidhormoner
- Peptider
- Aminosyror, peptider och proteiner
- Farmaceutiska förberedelser
- Farmakologiska åtgärder
- Kemiska åtgärder och användningar
- Terapeutisk användning
- Lösningar
- Specialanvändning av kemikalier
- Insulin, långverkande
- Insuliner
- Bukspottkörtelhormoner
- Proinsulin
- Insulin
- Oftalmiska lösningar
- Insulin, isofan
Andra studie-ID-nummer
- 77229224.8.0000.5404
- Topical Insulin (Annan identifierare: Unicamp)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
The de-identified dataset analyzed during the current study is available from the corresponding author on reasonable request.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .